Search

Displaying results 6141 - 6150 of 10000 in total
  1. Drug

    MLN8054

    go.drugbank.com/drugs/DB13061
    Investigational

    MLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.

  2. Drug

    Eliapixant

    go.drugbank.com/drugs/DB21465
    Investigational

    Eliapixant is under investigation in clinical trial NCT04614246 (Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive … The usage of the INN stem '-pixant' in the name indicates that Eliapixant is a purinoreceptor (P2X) antagonist.

  3. Drug

    Fradafiban

    go.drugbank.com/drugs/DB06472
    Experimental

  4. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

  5. Drug

    AM336

    go.drugbank.com/drugs/DB06563
    Experimental

    Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.

    Categories: Calcium Channels, N-Type
  6. Drug

    Refametinib

    go.drugbank.com/drugs/DB06309
    Investigational

  7. Drug

    Pelitinib

    go.drugbank.com/drugs/DB05524
    Investigational

    Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.

    Synonyms: (2E)-N-(4-((3-chloro-4-fluorophenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide
  8. Drug

    Bicifadine

    go.drugbank.com/drugs/DB04889
    Investigational

    It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. … Bicifadine was shown to have potent analgesic activity in vivo and was chosen for further development for the treatment of pain.

  9. Drug

    AZD2389

    go.drugbank.com/drugs/DB22104
    Investigational

    AZD2389 is an investigational small molecule inhibitor of fibroblast activation protein (FAP).[L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g. … NCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants).

  10. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.